Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables - Other (2019 - 2025)

Historic Receivables - Other for Corcept Therapeutics (CORT) over the last 7 years, with Q3 2025 value amounting to $3.9 million.

  • Corcept Therapeutics' Receivables - Other changed N/A to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is 8785.71% down from last year.
  • As of Q3 2025, Corcept Therapeutics' Receivables - Other stood at $3.9 million.
  • In the past 5 years, Corcept Therapeutics' Receivables - Other ranged from a high of $18.2 million in Q1 2025 and a low of $900000.0 during Q3 2022
  • Moreover, its 5-year median value for Receivables - Other was $3.1 million (2024), whereas its average is $6.1 million.
  • Data for Corcept Therapeutics' Receivables - Other shows a peak YoY increase of 145555.56% (in 2023) and a maximum YoY decrease of 8785.71% (in 2023) over the last 5 years.
  • Corcept Therapeutics' Receivables - Other (Quarter) stood at $1.4 million in 2021, then surged by 900.0% to $14.0 million in 2022, then crashed by 87.86% to $1.7 million in 2023, then soared by 141.18% to $4.1 million in 2024, then dropped by 4.88% to $3.9 million in 2025.
  • Its Receivables - Other was $3.9 million in Q3 2025, compared to $4.1 million in Q2 2025 and $18.2 million in Q1 2025.